You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,022,228

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,022,228

Title:	Crystal form of asenapine maleate
Abstract:	The invention relates to an orthorhombic crystal form of compound trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4- ,5-c]pyrrole(Z)-2-butenedioate, to methods for the preparation of this crystal form and to pharmaceutical compositions comprising an orthorhombic crystal form.
Inventor(s):	Heeres; Gerhardus Johannes (Oss, NL)
Assignee:	N.V. Organon (Oss, NL)
Application Number:	11/939,023
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,022,228
Patent Claims:	1. The compound trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4- ,5-c]pyrrole(Z)-2-butenedioate, wherein the compound is in a microcrystalline orthorhombic crystal form. 2. The microcrystalline form of the compound according to claim 1 which has a particle size distribution yielding a d95 value less than or equal to about 100 microns. 3. The microcrystalline form of the compound according to claim 2 which yields an X-ray powder diffraction pattern obtained with CuK.alpha. (radiation having peaks at values of 2-theta (20) of 10.5.degree. and 15.7.degree.. 4. The compound according to claim 1 which is characterized by an X-ray powder diffraction pattern obtained with CuK.alpha. radiation with peaks at values of 2-theta (2.theta.) of 10.5.degree., 15.7.degree., 18.3.degree., 19.0.degree., 22.2.degree., 23.2.degree. and 27.5.degree.. 5. A process for preparing an orthorhombic microcrystalline form trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4- -5,c]pyrrole(Z)-2-butenedioate, wherein the orthorhombic microcrystalline form of the compound is at least about 90 wt. % of compound, the process comprising crystallizing the compound from an ethanol/water mixture which is in a 9:1 volume proportion and micronizing said crystalline material thus obtained. 6. The microcrystalline form of the compound according to claim 2 which has a particle size distribution yielding a d95 value of less than or equal to about 50 microns. 7. The microcrystalline form of the compound according to claim 2 which has a particle size distribution yielding a d95 value of less than or equal to about 30 microns.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.